Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: An open label study
dc.contributor.buuauthor | Akkaya, Cengiz | |
dc.contributor.buuauthor | Sivrioğlu, Enver Yusuf | |
dc.contributor.buuauthor | Akgöz, Semra | |
dc.contributor.buuauthor | Eker, Salih Saygın | |
dc.contributor.buuauthor | Kirli, Selçuk | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | Q-9477-2019 | tr_TR |
dc.contributor.scopusid | 14061855100 | tr_TR |
dc.contributor.scopusid | 14062563200 | tr_TR |
dc.contributor.scopusid | 14061863400 | tr_TR |
dc.contributor.scopusid | 14019347700 | tr_TR |
dc.contributor.scopusid | 14019745700 | tr_TR |
dc.date.accessioned | 2021-11-17T06:22:54Z | |
dc.date.available | 2021-11-17T06:22:54Z | |
dc.date.issued | 2006-07 | |
dc.description.abstract | Objective The aim of this study was to compare the efficacy and tolerability of reboxetine in the treatment of major depressive disorder (MDD) and MDD with anxiety features to venlafaxine XR. Method Patients with MDD, aging 18 between 65 years, were randomly allocated to two groups receiving either open-label venlafaxine XR capsules (n = 50) or reboxetine tablets (n = 43). Subjects were administered Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Scale (HAM-A) at baseline and 2, 4, 7, 10 weeks after the baseline visit. Results Response rates to antidepressant treatment were significantly higher in the venlafaxine XR group at 10th week. When patients having anxious depression were analysed separately; response rate for anxiety of reboxetine group was significantly higher at 7th week only. Mean number of side effects were significantly higher in reboxetine group. Only one subject in each group was dropped out due to side effect. Conclusion We may suggest that reboxetine is as effective and tolerable as venlafaxine XR in the treatment of MDD and MDD with anxiety features, and it may be considered a treatment option to venlafaxine XR. | en_US |
dc.identifier.citation | Akkaya, C. vd. (2006). ''Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: An open label study''. Human Psychopharmacology, 21(5), 337-345. | en_US |
dc.identifier.endpage | 345 | tr_TR |
dc.identifier.issn | 0885-6222 | |
dc.identifier.issn | 1099-1077 | |
dc.identifier.issue | 5 | tr_TR |
dc.identifier.pubmed | 16856215 | tr_TR |
dc.identifier.scopus | 2-s2.0-33746958309 | tr_TR |
dc.identifier.startpage | 337 | tr_TR |
dc.identifier.uri | https://doi.org/10.1002/hup.770 | |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1002/hup.770 | |
dc.identifier.uri | http://hdl.handle.net/11452/22672 | |
dc.identifier.volume | 21 | tr_TR |
dc.identifier.wos | 000239669400007 | tr_TR |
dc.indexed.pubmed | Pubmed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.journal | Human Psychopharmacology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Neurosciences & neurology | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.subject | Psychology | en_US |
dc.subject | Psychiatry | en_US |
dc.subject | Venlafaxine | en_US |
dc.subject | Treatment | en_US |
dc.subject | Reboxetine | en_US |
dc.subject | Depression with anxiety features | en_US |
dc.subject | Depression | en_US |
dc.subject | Anxiety | en_US |
dc.subject | Lifetime | en_US |
dc.subject | Disorders | en_US |
dc.subject | Management | en_US |
dc.subject | Predictors | en_US |
dc.subject | Association | en_US |
dc.subject | Comorbidity | en_US |
dc.subject | Noradrenaline | en_US |
dc.subject | Relapse | en_US |
dc.subject | Fluoxetine | en_US |
dc.subject | Double-blind | en_US |
dc.subject.emtree | Venlafaxine | en_US |
dc.subject.emtree | Reboxetine | en_US |
dc.subject.emtree | Xerostomia | en_US |
dc.subject.emtree | Vertigo | en_US |
dc.subject.emtree | Sweating | en_US |
dc.subject.emtree | Statistical significance | en_US |
dc.subject.emtree | Side effect | en_US |
dc.subject.emtree | Randomized controlled trial | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Orthostatic hypotension | en_US |
dc.subject.emtree | Open study | en_US |
dc.subject.emtree | Nausea | en_US |
dc.subject.emtree | Muscle spasm | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Major depression | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Insomnia | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Hot flush | en_US |
dc.subject.emtree | Heart palpitation | en_US |
dc.subject.emtree | Headache | en_US |
dc.subject.emtree | Hamilton scale | en_US |
dc.subject.emtree | Hamilton anxiety scale | en_US |
dc.subject.emtree | Flushing | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Drug tolerability | en_US |
dc.subject.emtree | Drug safety | en_US |
dc.subject.emtree | Drug response | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Dizziness | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Controlled clinical trial | en_US |
dc.subject.emtree | Constipation | en_US |
dc.subject.emtree | Clinical trial | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Anxiety disorder | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.subject.mesh | Time factors | en_US |
dc.subject.mesh | Severity of Illness index | en_US |
dc.subject.mesh | Psychiatric status rating scales | en_US |
dc.subject.mesh | Morpholines | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Follow-up sstudies | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Drug evaluation | en_US |
dc.subject.mesh | Drug administration schedule | en_US |
dc.subject.mesh | Depressive disorder, major | en_US |
dc.subject.mesh | Delayed-action preparations | en_US |
dc.subject.mesh | Cyclohexanols | en_US |
dc.subject.mesh | Anxiety | en_US |
dc.subject.mesh | Antidepressive agents | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.scopus | Morpholines; Reboxetine; Amino Alcohols | en_US |
dc.subject.wos | Clinical neurology | en_US |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.subject.wos | Psychiatry | en_US |
dc.subject.wos | Psychology | en_US |
dc.title | Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: An open label study | en_US |
dc.type | Article | |
dc.wos.quartile | Q2 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: